Tailored strategies for improved control of CAR-T cells in multiple myeloma

Researchers assessed various strategies to control CAR-T cell toxicities in multiple myeloma. While dasatinib provides a rapid "off-switch," it lacks specificity by affecting all T cells. Antibody-dependent cell cytotoxicity is selective but requires NK cells often depleted by conditioning chemotherapy. Conversely, antibody-drug conjugates successfully eliminate targeted CAR-T cells independent of effector cells, offering a reliable safety mechanism.